Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer

As part of Rezon Bio's Executive Leadership Team, Dr. Scholze will lead the company's business development, marketing, market intelligence, proposal management, and project management teams. He will also oversee the company's commercial strategy, build strategic partnerships, support global growth, and help provide a smooth experience for customers.

Read Also- Personar Appoints Mike Slade as Senior Advisor to Support Global Growth

His appointment comes as Rezon Bio continues to expand its biologics CDMO services and strengthen its global presence. The company is investing in new capabilities, expertise, and partnerships to support both biosimilar and novel biologics projects, from early development to commercial manufacturing.

Dr. Scholze has more than 25 years of experience in biologics manufacturing, operations, and global business development. Before joining Rezon Bio, he led Global Business Development for Catalent's Core Biologics division, managing commercial activities for biologic drug development and manufacturing services.

“Hubert brings a unique combination of manufacturing expertise, commercial leadership and a deep understanding of the biologics industry and client needs,” said Dr. Adriana Kiędzierska-Mencfeld, Chief Executive Officer (CEO) of Rezon Bio. “His leadership will strengthen how we integrate commercial strategy, scientific excellence and operational execution to deliver greater value for our clients as our organization enters the next phase of growth.”

“I am excited to join Rezon Bio at such an important moment in the company’s journey,” said Dr. Scholze. “What attracted me the most is the proven track record, strong scientific and manufacturing expertise, and talented people who are passionate about delivering for their clients. Combined with a clear ambition for international growth, this creates a strong foundation for the future. I look forward to working with our teams and clients to build long-term partnerships, expand our global presence, and help bring innovative biologic therapies to patients worldwide.”

Rezon Bio is a Poland-based contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of mammalian biologic medicines.

The company provides end-to-end services, including cell line development, drug substance manufacturing, and drug product development. It supports customers with modern facilities, experienced teams, and a strong track record in meeting regulatory and commercial standards.

Built on the experience of Polpharma Biologics, Rezon Bio focuses on innovation, collaboration, and high-quality manufacturing to help bring biosimilars and new biologic medicines to patients around the world.